期刊
EMERGING INFECTIOUS DISEASES
卷 21, 期 7, 页码 1135-1143出版社
CENTERS DISEASE CONTROL
DOI: 10.3201/eid2107.150522
关键词
-
资金
- Defense Threat Reduction Agency
- Global Biosurveillance Technology Initiative
- US Agency for International Development
- Illumina
- National Institute of Allergy and Infectious Diseases [HH-SN272200700016I]
To support Liberia's response to the ongoing Ebola virus (EBOV) disease epidemic in Western Africa, we established in-country advanced genomic capabilities to monitor EBOV evolution. Twenty-five EBOV genomes were sequenced at the Liberian Institute for Biomedical Research, which provided an in-depth view of EBOV diversity in Liberia during September 2014-February 2015. These sequences were consistent with a single virus introduction to Liberia; however, shared ancestry with isolates from Mali indicated at least 1 additional instance of movement into or out of Liberia. The pace of change is generally consistent with previous estimates of mutation rate. We observed 23 nonsynonymous mutations and 1 nonsense mutation. Six of these changes are within known binding sites for sequence-based EBOV medical countermeasures; however, the diagnostic and therapeutic impact of EBOV evolution within Liberia appears to be low.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据